| payload |
{"created_at":"2026-04-21T03:09:54.871 {"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:c8675963390e38ad","evidence_event_ids":["evt_a5deb2537508"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-164090.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-164090.txt","company":"Tyra Biosciences, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-164090.txt","article_chars":1633,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_92e64b4e82a4564d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-164090.txt","content_type":"text/plain","enriched_at":"2026-04-21T07:24:48.083930+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-164090.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-164090.txt","source_event_id":"evt_a5deb2537508","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"61bbe25b2e7f21ee","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-20","2026-04-16","2036-04-15","2026-04-15"],"entities":[{"asset_class":"equity","name":"Tyra Biosciences, Inc.","relevance":"high","symbol":"TYRA","type":"issuer"},{"asset_class":"person","name":"Dable Habib J","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"person","name":"Ali D. Fawaz","relevance":"medium","symbol":"","type":"signatory"},{"asset_class":"company","name":"Pepgen Inc.","relevance":"low","symbol":"","type":"c/o address entity"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; no prior filing/position baseline is included.","The cleaned text shows \u201cStock Option (Right to Buy)\u201d and vesting terms, but does not clearly provide all option economics (e.g., exercise price, number of shares, or whether it is a grant vs exercise) in a fully readable labeled way beyond the vesting fraction statement.","The filing text includes additional numeric fields (e.g., \u201c35.12\u201d, \u201c44400\u201d, \u201c0\u201d, \u201cA\u201d, \u201cD\u201d, \u201c2036-04-15\u201d) but their exact mapping to specific Form 4 fields is not explicitly labeled in the provided excerpt, so they cannot be reliably interpreted beyond what is shown.","No explicit comparison to earlier holdings/transactions is included, so delta magnitude cannot be determined."],"key_facts":["SEC accession number: 0001193125-26-164090.","Form type: 4; issuer: Tyra Biosciences, Inc.; ticker: TYRA (as shown in the filing text).","Filed as of date: 2026-04-20; conform ed period of report: 2026-04-16.","Reporting person: Dable Habib J (CIK shown as 0001690773).","The filing includes disclosure text indicating a stock option (labeled \u201cStock Option (Right to Buy)\u201d).","The option-related disclosure includes a vesting statement: \u201c1/36th of the total number of shares of common stock subject to the option vest monthly following April 16, 2026, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date.\u201d","The filing includes a signature: \u201c/s/ Ali D. Fawaz, Attorney-in-Fact\u201d dated 2026-04-20."],"numeric_claims":[{"label":"Option vesting fraction per month","value":"1/36th"},{"label":"Vesting start date (grant date referenced)","value":"2026-04-16"},{"label":"Filing date (as of date)","value":"2026-04-20"},{"label":"Conformed period of report","value":"2026-04-16"}],"primary_claim":"On 2026-04-20, Tyra Biosciences, Inc. filed Form 4 (period of report 2026-04-16) disclosing a stock option grant/transaction by reporting person Dable Habib J with monthly vesting beginning after the 2026-04-16 grant date.","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Tyra Biosciences, Inc. (TYRA) filed a Form 4 on 2026-04-20 covering a transaction by reporting person Dable Habib J with respect to a stock option granted with a vesting schedule starting after 2026-04-16.","topics":["SEC Form 4","insider transaction","stock option","vesting schedule","Tyra Biosciences"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Tyra Biosciences, Inc. \u00b7 Filed 20260420","ticker":"TYRA","tickers":["TYRA"],"title":"TYRA filed 4","url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-164090.txt"}}... |